DBVT DBV Technologies S.A. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

DBVT [NASD]

DBV Technologies S.A.

Healthcare | Biotechnology | France

statements

Index	-	P/E	-	EPS (ttm)	-3.27	Insider Own	-	Shs Outstand	109.64M	Perf Week	-8.00%
Market Cap	176.52M	Forward P/E	-	EPS next Y	-2.52	Insider Trans	-	Shs Float	39.34M	Perf Month	-17.44%
Income	-	PEG	-	EPS next Q	-	Inst Own	49.15%	Short Float	0.69%	Perf Quarter	-63.49%
Sales	-	P/S	-	EPS this Y	-28.60%	Inst Trans	-	Short Ratio	0.47	Perf Half Y	-65.67%
Book/sh	3.98	P/B	0.40	EPS next Y	15.20%	ROA	-	Target Price	-	Perf Year	-78.73%
Cash/sh	-	P/C	-	EPS next 5Y	19.78%	ROE	-	52W Range	1.57 - 13.49	Perf YTD	-84.95%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-88.07%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	2.55%	ATR	0.09
Employees	311	Current Ratio	-	Sales Q/Q	-11.90%	Oper. Margin	-	RSI (14)	35.50	Volatility	4.58% 4.70%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.18	Prev Close	1.67
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	578.51K	Price	1.61
Recom	2.30	SMA20	-5.88%	SMA50	-17.71%	SMA200	-69.94%	Volume	102,425	Change	-3.59%

Aug-06-20

Downgrade

Societe Generale

Buy → Sell

Aug-05-20

Reiterated

H.C. Wainwright

Buy

$25 → $14

Mar-17-20

Downgrade

Stifel

Buy → Hold

$18 → $6

Jan-09-20

Upgrade

Stifel

Hold → Buy

$10 → $18

Dec-16-19

Initiated

Citigroup

Buy

Sep-05-19

Resumed

Morgan Stanley

Equal-Weight

Jun-17-19

Initiated

Goldman

Buy

Dec-20-18

Downgrade

Stifel

Buy → Hold

Dec-20-18

Downgrade

Jefferies

Buy → Hold

Dec-20-18

Downgrade

BofA/Merrill

Buy → Underperform

Dec-20-18

Downgrade

Barclays

Overweight → Equal Weight

Oct-31-17

Upgrade

Societe Generale

Sell → Hold

Oct-24-17

Downgrade

Societe Generale

Buy → Sell

Oct-23-17

Downgrade

Morgan Stanley

Overweight → Equal-Weight

Jun-23-17

Initiated

Deutsche Bank

Buy

$46

Mar-16-17

Upgrade

Societe Generale

Hold → Buy

Sep-26-16

Initiated

JMP Securities

Mkt Outperform

Dec-03-15

Initiated

Barclays

Overweight

$58

Oct-23-15

Initiated

BofA/Merrill

Buy

Oct-13-15

Initiated

Jefferies

Buy

$47

Oct-08-20 04:01PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2020 GlobeNewswire
Sep-15-20 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2020 GlobeNewswire
Sep-09-20 01:30AM	DBV Technologies Announces Leadership Changes GlobeNewswire
Sep-02-20 04:30PM	DBV Technologies to Participate in Multiple September Investor Conferences GlobeNewswire
Aug-12-20 04:01PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2020 GlobeNewswire
Aug-11-20 10:59AM	Could This Small-Cap Biotech Stock Make You Rich? Motley Fool
Aug-05-20 08:17AM	DBV discloses FDA concerns about experimental peanut allergy treatment MarketWatch +5.98%
Aug-04-20 05:09PM	SHAREHOLDER ALERT: Investigation of DBV Technologies Announced by Holzer & Holzer, LLC Business Wire -42.93%
12:06PM	Why DBV Technologies Stock Is Plunging Today Motley Fool
01:30AM	DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years GlobeNewswire
Jul-31-20 01:30AM	DBV Technologies Reports First Half 2020 Financial Results GlobeNewswire +6.75%
Jul-20-20 04:01PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF GlobeNewswire
Jul-15-20 04:01PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2020 GlobeNewswire +8.66%
Jul-10-20 09:00AM	DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology GlobeNewswire
Jul-07-20 09:30PM	Here is What Hedge Funds Think About DBV Technologies SA (DBVT) Insider Monkey
Jun-26-20 08:28AM	The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts Benzinga -13.70%
02:30AM	DBV Technologies Provides Operational and Business Update GlobeNewswire
Jun-11-20 04:01PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020 GlobeNewswire -8.02%
Jun-04-20 04:30PM	DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020 GlobeNewswire
Jun-02-20 04:30PM	DBV Technologies To Present at the Goldman Sachs 41st Annual Global Healthcare Conference GlobeNewswire
May-12-20 04:01PM	Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020 GlobeNewswire
Apr-30-20 04:01PM	DBV Technologies Reports March 31, 2020 Cash Position GlobeNewswire
Apr-20-20 04:01PM	DBV Technologies Announces Results of its 2020 Ordinary and Extraordinary General Meeting GlobeNewswire
Apr-15-20 06:00AM	Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire -8.21%
Apr-10-20 04:01PM	Ordinary and Extraordinary General Meeting of April 20, 2020 to be Held in Closed Virtual Session Due to COVID-19 Pandemic GlobeNewswire
Mar-31-20 03:46AM	Analysts Just Made A Major Revision To Their DBV Technologies S.A. (EPA:DBV) Revenue Forecasts Simply Wall St.
Mar-30-20 04:01PM	Ordinary and Extraordinary General Meeting of April 20, 2020 GlobeNewswire
Mar-26-20 11:00AM	Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Mar-20-20 04:15PM	DBV Technologies Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F GlobeNewswire +9.73%
Mar-17-20 04:00PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 29, 2020 and March 4, 2020 GlobeNewswire -55.70%
03:00PM	DBVT Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of DBV Technologies S.A. and Encourages Investors to Contact the Firm ACCESSWIRE
02:51PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT GlobeNewswire
08:48AM	The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment Benzinga
Mar-16-20 04:30PM	DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years GlobeNewswire -10.70%
Mar-09-20 02:58AM	Did You Manage To Avoid DBV Technologies's (EPA:DBV) Devastating 77% Share Price Drop? Simply Wall St. -5.89%
Mar-05-20 11:09AM	3 Top Biotech Stocks With Major Catalysts Approaching TipRanks -8.52%
Mar-04-20 04:30PM	DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business Update GlobeNewswire
04:01PM	DBV Technologies Announces Closing of Underwriters Option to Purchase Additional Ordinary Shares in the Form of American Depositary Shares in Connection With its Global Offering GlobeNewswire
Mar-02-20 01:30AM	DBV Technologies Announces Partial Exercise of Underwriters Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs) GlobeNewswire
Feb-24-20 04:00PM	DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020 GlobeNewswire
Feb-21-20 09:29AM	DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children GlobeNewswire
Feb-10-20 04:00PM	DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference GlobeNewswire
Feb-06-20 08:00PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2020 and February 4, 2020 GlobeNewswire
04:01PM	DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer GlobeNewswire
Feb-04-20 04:30PM	DBV Technologies Announces Closing of Global Offering GlobeNewswire
Feb-01-20 03:53PM	Aimmune's 'First-Of-Its-Kind' Peanut Allergy Drug Receives FDA Approval Benzinga
Jan-30-20 01:30AM	DBV Technologies Announces Pricing of $153.7 million (139.8 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares GlobeNewswire -13.15%
Jan-29-20 04:05PM	DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports December 31, 2019 Cash Position GlobeNewswire
Jan-15-20 04:00PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF GlobeNewswire
Jan-14-20 04:00PM	Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Jan-10-20 08:18AM	DBV Technologies is in Overbought Territory: What???s Next? Zacks
Jan-09-20 08:39AM	The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results Benzinga +14.77%
Jan-08-20 04:30PM	DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy GlobeNewswire
Jan-02-20 04:30PM	DBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial Officer GlobeNewswire
Dec-17-19 04:06PM	Hedge Funds Are Dumping DBV Technologies SA ADR (DBVT) Insider Monkey
Dec-10-19 04:00PM	Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Nov-19-19 04:00PM	Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Nov-05-19 04:30PM	DBV Technologies to Present at the Stifel 2019 Healthcare Conference GlobeNewswire
Oct-30-19 08:39PM	Heres What Hedge Funds Think About DBV Technologies SA ADR (DBVT) Insider Monkey
Oct-24-19 04:01PM	DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019 GlobeNewswire
Oct-16-19 06:30AM	Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire +5.64%
Oct-15-19 04:30PM	DBV Technologies Announces Closing of Global Offering GlobeNewswire +7.77%
Oct-10-19 01:30AM	DBV Technologies Announces Full Exercise of Underwriters Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs) GlobeNewswire
Oct-09-19 01:30AM	DBV Technologies Announces Pricing of $125 million (114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares GlobeNewswire -7.62%
Oct-08-19 04:18PM	DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position GlobeNewswire -10.58%
Oct-04-19 11:45AM	DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy GlobeNewswire
Oct-02-19 04:00PM	Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Sep-19-19 04:00PM	Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Sep-17-19 06:28AM	Does Market Volatility Impact DBV Technologies S.A.'s (EPA:DBV) Share Price? Simply Wall St.
Sep-16-19 04:19PM	Analyst: DBV's Peanut Allergy Drug Could Outscore Aimmune's On Safety Front Benzinga
Aug-08-19 09:53AM	DBV Resubmits Regulatory Application For Peanut Allergy Drug, Stock Rallies Benzinga +9.52%
Aug-07-19 04:05PM	DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy GlobeNewswire
Aug-01-19 01:30AM	DBV Technologies Reports First Half 2019 Financial Results GlobeNewswire
Jul-19-19 09:06AM	If You Had Bought DBV Technologies (EPA:DBV) Stock Three Years Ago, You'd Be Sitting On A 71% Loss, Today Simply Wall St.
Jul-18-19 01:30AM	Amendment to the DBV Technologies Liquidity Contract with NATIXIS ODDO BHF and Half-Year Report GlobeNewswire
Jul-12-19 06:00AM	Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Jul-11-19 06:51PM	Here's Why Aimmune Therapeutics Fell 7% Today Motley Fool
Jun-26-19 01:30AM	DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical Officer GlobeNewswire
Jun-12-19 09:00AM	DBV Technologies S.A. (DBVT) Moves to Buy: Rationale Behind the Upgrade Zacks
Jun-11-19 08:00AM	Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Jun-03-19 01:30AM	DBV Technologies to Attend Upcoming Investor Conferences GlobeNewswire
Jun-01-19 08:00AM	DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019 GlobeNewswire
May-24-19 04:30PM	DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors GlobeNewswire
May-14-19 01:30AM	DBV Technologies Announces Departure of Deputy CEO David Schilansky GlobeNewswire +5.39%
May-11-19 01:27PM	Did Hedge Funds Drop The Ball On DBV Technologies SA ADR (DBVT) ? Insider Monkey
May-06-19 03:30AM	Ordinary and Extraordinary General Meeting of May 24, 2019 - Procedures for Obtaining Preparatory Documents for the General Meeting GlobeNewswire
May-02-19 01:30AM	DBV Technologies to Attend Upcoming Investor Conferences GlobeNewswire
Apr-30-19 01:30AM	DBV Technologies Reports March 31, 2019 Cash Position GlobeNewswire
Apr-11-19 09:17AM	DBV Technologies S.A. (DBVT) Shares March Higher, Can It Continue? Zacks
Apr-08-19 04:30PM	DBV Technologies Announces Closing of Global Offering GlobeNewswire
11:00AM	Monthly information regarding the total number of voting rights and total number of shares of the Company GlobeNewswire
Apr-05-19 01:30AM	DBV Technologies Announces Full Exercise of Underwriters Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (ADS) GlobeNewswire
Apr-04-19 04:36PM	Why DBV Technologies Shares Soared Today Motley Fool +11.73%
02:00AM	DBV Technologies Announces Pricing of $70.4 million (62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares GlobeNewswire
Apr-03-19 04:05PM	DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares GlobeNewswire
Apr-01-19 05:00PM	DBV Technologies Announces Filing of 2018 Document de Référence and 2018 Annual Report on Form 20-F GlobeNewswire
Mar-28-19 04:06PM	Lifshitz & Miller LLP Announces Investigation of Atlas Financial Holdings, Inc., Conduent, Inc., DBV Technologies SA, Ebix, Inc., FTS International, Inc., NV5 Global, Inc., and Venator Materials PLC PR Newswire
Mar-25-19 04:26PM	Peninsula biotech lines up chance to crack the peanut allergy nut American City Business Journals
Mar-19-19 06:39PM	Cohen Milstein Sellers & Toll PLLC Announces Investigation of DBV Technologies S.A. Business Wire
Mar-18-19 03:00PM	FINAL DEADLINE: (DBVT) DBV Technologies S.A. Bronstein, Gewirtz & Grossman, LLC - March 18, 2019 GlobeNewswire

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has a collaboration with Nestle Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience